Bavarian Nordic A/S
CSE:BAVA
Bavarian Nordic A/S
Other Receivables
Bavarian Nordic A/S
Other Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Other Receivables
kr40.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
Genmab A/S
CSE:GMAB
|
Other Receivables
kr101m
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Other Receivables
kr97.4m
|
CAGR 3-Years
38%
|
CAGR 5-Years
45%
|
CAGR 10-Years
26%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Other Receivables
€11.2m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
26%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Other Receivables
kr9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Saniona AB
STO:SANION
|
Other Receivables
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bavarian Nordic A/S
Glance View
Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.
See Also
What is Bavarian Nordic A/S's Other Receivables?
Other Receivables
40.2m
DKK
Based on the financial report for Dec 31, 2024, Bavarian Nordic A/S's Other Receivables amounts to 40.2m DKK.
What is Bavarian Nordic A/S's Other Receivables growth rate?
Other Receivables CAGR 10Y
8%
Over the last year, the Other Receivables growth was -14%. The average annual Other Receivables growth rates for Bavarian Nordic A/S have been -10% over the past three years , 10% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet